These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 17852869)

  • 1. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.
    Leach ST; Yang Z; Messina I; Song C; Geczy CL; Cunningham AM; Day AS
    Scand J Gastroenterol; 2007 Nov; 42(11):1321-31. PubMed ID: 17852869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease.
    Foell D; Wittkowski H; Ren Z; Turton J; Pang G; Daebritz J; Ehrchen J; Heidemann J; Borody T; Roth J; Clancy R
    J Pathol; 2008 Oct; 216(2):183-92. PubMed ID: 18729068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: calprotectin and IL-6 changes do not correspond to sRAGE changes.
    Malícková K; Kalousová M; Fucíková T; Bortlík M; Duricová D; Komárek V; Zima T; Janatková I; Lukás M
    Scand J Clin Lab Invest; 2010 Jul; 70(4):294-9. PubMed ID: 20446880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage.
    Foell D; Wittkowski H; Roth J
    Gut; 2009 Jun; 58(6):859-68. PubMed ID: 19136508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12.
    Wittkowski H; Hirono K; Ichida F; Vogl T; Ye F; Yanlin X; Saito K; Uese K; Miyawaki T; Viemann D; Roth J; Foell D
    Arthritis Rheum; 2007 Dec; 56(12):4174-81. PubMed ID: 18050248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease.
    Fagerberg UL; Lööf L; Lindholm J; Hansson LO; Finkel Y
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):414-20. PubMed ID: 18030206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.
    Kolho KL; Raivio T; Lindahl H; Savilahti E
    Scand J Gastroenterol; 2006 Jun; 41(6):720-5. PubMed ID: 16716972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis.
    Chen YS; Yan W; Geczy CL; Brown MA; Thomas R
    Arthritis Res Ther; 2009; 11(2):R39. PubMed ID: 19284577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA; Leach ST; Day AS
    Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients.
    Brown KA; Back SJ; Ruchelli ED; Markowitz J; Mascarenhas M; Verma R; Piccoli DA; Baldassano RN
    Am J Gastroenterol; 2002 Oct; 97(10):2603-8. PubMed ID: 12385446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal expression of S100A12 (calgranulin C) and S100A8/A9 (calprotectin) and correlation with serum and fecal concentrations in dogs with chronic inflammatory enteropathy.
    Heilmann RM; Nestler J; Schwarz J; Grützner N; Ambrus A; Seeger J; Suchodolski JS; Steiner JM; Gurtner C
    Vet Immunol Immunopathol; 2019 May; 211():64-74. PubMed ID: 31084897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
    Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
    Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
    Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
    Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.
    Myles A; Viswanath V; Singh YP; Aggarwal A
    J Rheumatol; 2011 Sep; 38(9):1994-9. PubMed ID: 21724696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease.
    Kruidenier L; Kuiper I; van Duijn W; Marklund SL; van Hogezand RA; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):7-16. PubMed ID: 12950012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice.
    Berni Canani R; Rapacciuolo L; Romano MT; Tanturri de Horatio L; Terrin G; Manguso F; Cirillo P; Paparo F; Troncone R
    Dig Liver Dis; 2004 Jul; 36(7):467-70. PubMed ID: 15285526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.
    Sipponen T; Haapamäki J; Savilahti E; Alfthan H; Hämäläinen E; Rautiainen H; Koskenpato J; Nuutinen H; Färkkilä M
    Scand J Gastroenterol; 2012 Jul; 47(7):778-84. PubMed ID: 22519419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.